Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Expert consensus conference and conceptual framework recommendations without new empirical human data
PubMed 21514248 · doi:10.1016/j.jalz.2011.03.003
What was done
An international workgroup convened by the National Institute on Aging and the Alzheimer's Association reviewed biomarker, epidemiological, and neuropsychological literature to establish a conceptual framework and operational research criteria for preclinical Alzheimer's disease.
What was found
No quantitative findings, statistical metrics, or effect sizes are reported in the abstract. The workgroup defined theoretical stages and operational research criteria to model disease progression from normal cognition to mild cognitive impairment and dementia.
Why it matters
This framework established standardized terminology and research criteria to investigate Alzheimer's disease pathology prior to symptom onset, enabling early-stage intervention research.
Limits
The paper provides consensus guidelines and theoretical framework proposals rather than new empirical data or test accuracy metrics. The proposed criteria were designed solely for research purposes and lacked validation for clinical diagnostic use at the time of publication.
Cited by
- supports Amyloid and tau pathology can accumulate in the brain 10 to 15 years before clinical cognitive complaints appear in Alzheimer's disease.